Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — H1 2018/19 Earnings Presentation
8 slides from Coloplast A/s Class B's earnings presentation, May 2, 2019
Slide 1: Coloplast Earnings Conference Call H1 2018/19
Coloplast Earnings Conference Call H1 2018/19 2 May 2019
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid underlying performance in Q2 and reported growth guidance for 2018/19 increased to ~9%
Solid underlying performance in Q2 and reported growth guidance for 2018/19 increased to ~9% due to currencies Q2 Highlights Revenue growth +9% • Organic growth of 8% and 9% in DKK Reported revenue (DKKm) +8% • Strong growth in Continence Care, Wound Care and Organic growth +9% 8,722 Interventional
Slide 4: Solid growth across all business areas in Europe, US and China
Solid growth across all business areas in Europe, US and China H1 18/19 revenue by business area H1 18/19 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm growth area DKKm growth Ostomy Care 3,478 7%
Slide 5: H1 18/19 reported revenue grew 9% driven by solid organic growth of 8%
H1 18/19 reported revenue grew 9% driven by solid organic growth of 8% Comments Revenue development • H1 2018/19 reported revenue increased by DKK 732m (DKKm) or 9% compared to H1 2017/18 55 39 8,722 • The majority of growth was driven by organic growth 638 contributing DKK 638m or 8% to reported re
Slide 6: Solid growth in EBIT of 12% in Q2 and 10% in H1
Solid growth in EBIT of 12% in Q2 and 10% in H1 Comments EBIT margin development (%) • EBIT increased 10% to DKK 2,639m with a reported margin of 30% compared to 30% last year • Gross margin of 67% in DKK compared to 67% same period last year • Positive impact from operational leverage, continued ef
Slide 7: Updated guidance for FY 2018/19
Updated guidance for FY 2018/19 Guidance 2018/19 Guidance 2018/19 (DKK)* Key assumptions Sales growth ~8% ~9% • Up to 1% negative price pressure (organic) (previously 8-9%) • DKK guidance includes growth from Lilial and IncoCare • Incremental investments of up to 2% of revenue • Restructuring costs
Slide 8: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /